Currently, the detection of crude buckwheat extract-specific IgE by ImmunoCAP (f11) (Phadia AB, Uppsala, Sweden) is widely used to diagnose buckwheat allergy. However, the results of this test do not always correlate with the development of allergic symptoms. This study aimed to evaluate the diagnostic usefulness of specific IgE antibody titers for the major buckwheat allergens Fag e 1 and Fag e 2. Specific IgE antibodies were determined using the ImmunoCAP method for native Fag e 1 and Fag e 2, recombinant Fag e 1 and Fag e 2, and crude buckwheat extract (f11) in 10 buckwheat allergy patients, 14 atopic dermatitis patients, and 15 healthy subjects. All buckwheat allergy patients showed positive results for native Fag e 1- and Fag e 2-specific IgE tests and for ImmunoCAP (f11). In contrast, the rates of atopic dermatitis patients with positive results for native Fag e 1- and Fag e 2-specific IgE tests were 64.2% (9/14) and 57.1% (8/14), respectively. The sensitivities of the test using recombinant proteins were lower than those of the test using native proteins. The area under the curve (AUC) as determined by receiver operating characteristic (ROC) curve analysis was the largest for the native Fag e 2-specific IgE test (0.967), with a sensitivity of 90% and a specificity of 89.6% (cut-off: 2.74 kUa/L). Thus, the native Fag e 2-specific IgE antibody titer obtained using the ImmunoCAP method is more reliable than the buckwheat ImmunoCAP (f11) value for predicting buckwheat allergy.

We describe here a 35-year-old Japanese woman with mycosis fungoides (MF) who developed numerous, rapidly-growing, seborrheic keratoses on the front of her neck and chest. To the best of our knowledge, this is the first reported case of MF with Leser-Trélat sign from Japan.

Pruritus is a condition in which itch occurs in the absence of apparent skin lesions.It is sometimes unresponsive to treatment with topical moisturizers and often is unresponsive to antihistamines. We evaluated the antipruritic effects of Neurotropin injections in patients with moisturizer-and antihistamine-resistant pruritus. We monitored these patients by itch scores recorded in symptom diaries, as well as reports of quality of life (QOL). This study investigated both the efficacy and safety of Neurotropin injections using an open-label study design. We enrolled 40 patients from six participating study sites. Of the 40 patients that were initially enrolled, six patients were ineligible, and ultimately, 33 were included for evaluation after one patient dropped out. Neurotropin was administered by subcutaneous injection to 22 patients and intravenous injection to 11 patients at a frequency of once per week.Compared to data collected during a one-week observation period prior to treatment, after seven injections of Neurotropin, there was a significant improvement in the Shiratori symptom severity score and the visual analog scale (VAS) scores for itch symptoms, and the Dermatology Life Quality Index (DLQI) for quality of life. No new adverse events occurred during the period of investigation. A notable benefit to Neurotropin is that it can be used in patients with renal impairment and patients receiving dialysis therapy. Our results demonstrated that Neurotropin is effective in the treatment of moisturizer-and antihistamine-resistant pruritus.

No abstract

A grandfather and granddaughter suffering from sporotrichosis were reported. It is thought that they might have been infected from the same source of Sporothrix schenckii (S. schenckii).